IP Verse

Anti-Il1Rap Antibodies And Their Use For Treating Human - EP3020730

The patent EP3020730 was granted to Cantargia on Dec 26, 2018. The application was originally filed on Jan 19, 2012 under application number EP15197139A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3020730

CANTARGIA
Application Number
EP15197139A
Filing Date
Jan 19, 2012
Status
Opposition Rejected
May 24, 2024
Grant Date
Dec 26, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MAB DISCOVERYSep 25, 2019ZWICKERWITHDRAWN

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0213303
DESCRIPTIONUS4235871
DESCRIPTIONUS4816567
DESCRIPTIONUS5851451
OPPOSITIONEP2665749
OPPOSITIONUS2006019256
OPPOSITIONWO2012098407
SEARCHWO9623067

Non-Patent Literature (NPL) Citations (68) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BHATIA M; WANG JC; KAPP U; BONNET D; DICK JE, "Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice", PROC NATL ACAD SCI USA., (1997), vol. 94, pages 5320 - 5325-
DESCRIPTION- BOERNER ET AL., J. LMMUNOL., (1991), vol. 147, pages 86 - 95-
DESCRIPTION- BUNKA DH; STOCKLEY PG, NAT REV MICROBIOL., (2006), vol. 4, no. 8, pages 588 - 96-
DESCRIPTION- CASTOR A; NILSSON L; ASTRAND-GRUNDSTROM / ET AL., "Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia", NAT MED., (2005), vol. 11, pages 630 - 637-
DESCRIPTION- COLE ET AL., MOL. CELL. BIOL., (1984), vol. 62, pages 109 - 120-
DESCRIPTION- COLE ET AL., Monoclonal antibodies and Cancer Therapy, ALAN R. LISS, (1985), page 77-
DESCRIPTION- COPLAND M; HAMILTON A; ELRICK LJ ET AL., "Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction", BLOOD, (2006), vol. 107, pages 4532 - 4539-
DESCRIPTION- COTE ET AL., PROC. NATL. ACAD. SCI. USA, (1983), vol. 80, pages 2026 - 2030-
DESCRIPTION- DEININGER MW; GOLDMAN JM; MELO JV, "The molecular biology of chronic myeloid leukemia", BLOOD, (2000), vol. 96, pages 3343 - 3356, XP002454148-
DESCRIPTION- DRABOVICH, ANAL CHEM., (2006), vol. 78, no. 9, pages 3171 - 8-
DESCRIPTION- EISTERER W; JIANG X; CHRIST O, "Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease", LEUKEMIA, (2005), vol. 19, pages 435 - 441-
DESCRIPTION- EMA H; MORITA Y; YAMAZAKI S ET AL., "Adult mouse hematopoietic stem cells: purification and single-cell assays", NAT PROTOC., (2006), vol. 1, pages 2979 - 2987-
DESCRIPTION- ESTROV Z ET AL., "Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of lL-1 activity", BLOOD, (1991), vol. 78, pages 1476 - 1484-
DESCRIPTION- FIALKOW PJ; DENMAN AM; JACOBSON RJ; LOWENTHAL MN, "Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells", J CLIN INVEST., (1978), vol. 62, pages 815 - 823-
DESCRIPTION- FIELDS; SONG, NATURE, (1989), vol. 340, pages 245 - 246-
DESCRIPTION- GRAHAM SM; JORGENSEN HG; ALLAN E ET AL., "Primitive, quiescent, Philadelphiapositive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro", BLOOD, (2002), vol. 99, pages 319 - 325-
DESCRIPTION- HOGGE DE ET AL., "Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor", BLOOD, (1996), vol. 88, pages 3765 - 3773, XP009166806-
DESCRIPTION- HOOGENBOOM; WINTER, J. MOL. BIOL., (1991), vol. 227, page 381-
DESCRIPTION- HOPPE-SEYLER; BUTZ, J MOL MED., (2000), vol. 78, no. 8, pages 426 - 30-
DESCRIPTION- HUANG ET AL., PROC. NATL. ACAD. SCI. USA., (1997), vol. 94, no. 24, pages 12829 - 12832-
DESCRIPTION- HYSTAD ME; MYKLEBUST JH; BO TH ET AL., "Characterization of early stages of human B cell development by gene expression profiling", J IMMUNOL., (2007), vol. 179, pages 3662 - 3671-
DESCRIPTION- JIANG X; ZHAO Y; FORREST D; SMITH C; EAVES A; EAVES C, "Stem cell biomarkers in chronic myeloid leukemia", DIS MARKERS, (2008), vol. 24, pages 201 - 216-
DESCRIPTION- JIANG X; ZHAO Y; SMITH C ET AL., "Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies", LEUKEMIA, (2007), vol. 21, pages 926 - 935-
DESCRIPTION- JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525-
DESCRIPTION- JONES, NATURE, (1986), vol. 321, pages 522 - 525-
DESCRIPTION- JORGENSEN HG; ALLAN EK; JORDANIDES NE; MOUNTFORD JC; HOLYOAKE TL, "Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells", BLOOD, (2007), vol. 109, pages 4016 - 4019-
DESCRIPTION- KAVALERCHIK E; GOFF D; JAMIESON CH, "Chronic myeloid leukemia stem cells", J CLIN ONCOL., (2008), vol. 26, pages 2911 - 2915-
DESCRIPTION- KIEL MJ; YILMAZ OH; IWASHITA T; TERHORST C; MORRISON SJ, "SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells", CELL, (2005), vol. 121, pages 1109 - 1121-
DESCRIPTION- KOHLER ET AL., NATURE, (1975), vol. 256, page 4950497-
DESCRIPTION- KOZBOR ET AL., J. IMMUNOL. METHODS, (1985), vol. 81, pages 31 - 42-
DESCRIPTION- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, page 581-
DESCRIPTION- MORRIS JC; WALDMANN TA, "Antibody-based therapy of leukaemia", EXPERT REV MOL MED., (2009), vol. 11, page E29-
DESCRIPTION- NILSSON M; KARLSSON S; FAN X, "Functionally distinct subpopulations of cord blood CD34+ cells are transduced by adenoviral vectors with serotype 5 or 35 tropism", MOL THER., (2004), vol. 9, pages 377 - 388-
DESCRIPTION- ORLANDI, PROC. NATL. ACAD. SCI. U.S.A., (1989), vol. 86, pages 3833 - 3837-
DESCRIPTION- PLANT ET AL., ANALYT BIOCHEM, (1995), vol. 226, no. 2, pages 342 - 348-
DESCRIPTION- PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596-
DESCRIPTION- REICHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327-
DESCRIPTION- RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329-
DESCRIPTION- SKERRA, CURR OPIN BIOTECHNOL., (200708), vol. 18, no. 4, pages 295 - 304-
DESCRIPTION- TAVOR S; PETIT /; POROZOV S ET AL., "CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice", CANCER RES., (2004), vol. 64, pages 2817 - 2824-
DESCRIPTION- VERHOEYEN, SCIENCE, (1988), vol. 239, pages 1534 - 15361-
DESCRIPTION- VISVADER; LINDEMAN, NAT REV CANCER, (2008), vol. 8, pages 755 - 768-
DESCRIPTION- WINTER ET AL., NATURE, (1991), vol. 349, pages 293 - 299-
DESCRIPTION- MAJETI R; CHAO MP; ALIZADEH AA ET AL., "CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells", CELL, (2009), vol. 138, doi:doi:10.1016/j.cell.2009.05.045, pages 286 - 299, XP055277135
DESCRIPTION- SUBRAMANIAM S; STANSBERG C; CUNNINGHAM C, "The interleukin 1 receptor family", DEV COMP IMMUNOL., (2004), vol. 28, doi:doi:10.1016/j.dci.2003.09.016, pages 415 - 428, XP008072560
DESCRIPTION- JARAS M; JOHNELS P; AGERSTAM H ET AL., "Expression of P190 and P210 BCR/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STATS-dependent expansion of the erythroid lineage", EXP HEMATOL., (2009), vol. 37, doi:doi:10.1016/j.exphem.2008.11.003, pages 367 - 375, XP025942502
DESCRIPTION- JIN L; LEE EM; RAMSHAW HS ET AL., "Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells", CELL STEM CELL, (2009), vol. 5, doi:doi:10.1016/J.STEM.2009.04.018, pages 31 - 42, XP002680506
DESCRIPTION- WILKINSON RW; LEE-MACARY AE; DAVIES D; SNARY D; ROSS EL, "Antibodydependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores", J IMMUNOL METHODS, (2001), vol. 258, doi:doi:10.1016/S0022-1759(01)00474-4, pages 183 - 191, XP004311928
DESCRIPTION- JIN L; HOPE KJ; ZHAI Q; SMADJA-JOFFE F; DICK JE, "Targeting of CD44 eradicates human acute myeloid leukemic stem cells", NAT MED., (2006), vol. 12, doi:doi:10.1038/nm1483, pages 1167 - 1174, XP002457833
DESCRIPTION- HOSEN N ET AL., "CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia", PROC NATL ACAD SCI USA., (2007), vol. 104, doi:doi:10.1073/pnas.0704271104, pages 11008 - 11013, XP008109009
DESCRIPTION- ALI S; HUBER M; KOLLEWE C; BISCHOFF SC; FALK W; MARTIN MU, "IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells", PROC NATL ACAD SCI USA., (2007), vol. 104, doi:doi:10.1073/pnas.0705939104, pages 18660 - 18665, XP009169532
DESCRIPTION- VAN RHENEN A; VAN DONGEN GA; KELDER A ET AL., "The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells", BLOOD, (2007), vol. 110, doi:doi:10.1182/BLOOD-2007-03-083048, pages 2659 - 2666, XP002632479
DESCRIPTION- DICK JE, "Stem cell concepts renew cancer research", BLOOD, (2008), vol. 112, doi:doi:10.1182/blood-2008-08-077941, pages 4793 - 4807, XP009136497
EXAMINATION- Serengulam V. Govindan ET AL, "New Antibody Conjugates in Cancer Therapy", The Scientific World JOURNAL, (20100101), vol. 10, doi:10.1100/tsw.2010.191, pages 2070 - 2089, XP055319602
OPPOSITION- BEN-KASUS, "Cancer therapeutic antibodies come of age: Targeting minimal residual disease", Mol. Onkol., (20070000), vol. 1, doi:10.1016/j.molonc.2007.01.003, ISSN 1574-7891, pages 42 - 54, XP022072040-
OPPOSITION- CULLINAN et al., "IL-1 Receptor Accessory Protein Is an Essential Component of the IL-1 Receptor", J. Immunol., (19980000), vol. 161, no. 10, pages 5614 - 5620, XP055486650-
OPPOSITION- DINARELLO, "Why not treat human cancer with interleukin-1 blockade?", Cancer Metastasis Rev, (20100000), vol. 29, pages 317 - 329, XP019815068-
OPPOSITION- SU et al., "Molecular Clarification of Human Carcinomas by Use of Gene Expression Signatures", Cancer Research, (20010000), vol. 61, no. 20, pages 7388 - 7393, XP002255758-
OPPOSITION- YOON et al., "Antibodies to domains II and III of the IL-1 receptor accessory protein inhibit IL-1 beta activity but not binding: regulation of IL-1 responses is via type I receptor, not the accessory protein.", J. Immunol., (19980000), vol. 160, no. 7, pages 3170 - 3179, XP055191790-
OPPOSITION- JARAS et al., "Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein", PNAS, (20100000), vol. 107, no. 37, doi:10.1073/PNAS.1004408107, pages 16280 - 16285, XP002674632
OPPOSITION- BRIKOS et al., "Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components.", Molecular and Cellular Proteomics, (20070000), vol. 6, no. 9, doi:10.1074/mcp.M600455-MCP200, ISSN 1535-9476, pages 1551 - 1559, XP055635139
OPPOSITION- VON MEHREN et al., "Monoclonal Antibody Therapy For Cancer", Annu. Rev. Med., (20030000), vol. 54, pages 343 - 369, XP008030292
OPPOSITION- TALANTOV et al., "Novel Genes Associated with Malignant Melanoma but not Benign Melanocytic Lesions", Clin. Can. Res., (20050000), vol. 11, no. 20, doi:10.1158/1078-0432.CCR-05-0683, ISSN 1078-0432, pages 7234 - 7242, XP002377436
OPPOSITION- BALAGURUNATHAN et al., "Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer", Mol. Cancer Ther., (20080000), vol. 7, no. 9, doi:10.1158/1535-7163.MCT-08-0402, ISSN 1535-7163, pages 3071 - 3080, XP055165836
OPPOSITION- LEWIS, ANNE M. et al., "Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment.", J. Translat. Med., (20060000), vol. 4, no. 48, doi:10.1186/1479-5876-4-48, ISSN 1479-5876, pages 1 - 12, XP055567277
SEARCH- BALAGURUNATHAN YOGANAND ET AL, "Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, (20080901), vol. 7, no. 9, ISSN 1535-7163, pages 3071 - 3080, XP009129600 [A] 1-15 * page 3077; table 2 * * page 3076 *-
SEARCH- SOURABH GHOSH ET AL, "Three-dimensional culture of melanoma cells profoundly affects gene expression profile: A high density oligonucleotide array study", JOURNAL OF CELLULAR PHYSIOLOGY, (20050801), vol. 204, no. 2, doi:10.1002/jcp.20320, ISSN 0021-9541, pages 522 - 531, XP055167052 [A] 1-15 * table 2 *
SEARCH- JÄRÅS MARCUS ET AL, "Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 14 SEP 2010 LNKD- PUBMED:20805474, (20100914), vol. 107, no. 37, ISSN 1091-6490, pages 16280 - 16285, XP002674632 [I] 1-15 * page 16282&5, column left *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents